You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
紅日藥業(300026.SZ)獲得天津市科學技術進步一等獎
格隆匯 04-16 19:46

格隆匯4月16日丨紅日藥業(300026.SZ)公佈,公司於近日獲得由天津市科學技術局授予的“天津市科學技術進步一等獎”,目前已完成公示。

項目名稱:血必淨注射液治療新型冠狀病毒感染的肺炎療效的臨牀和機制研究;主要完成單位:天津紅日藥業股份有限公司、廣州醫科大學附屬第一醫院、廣州呼吸健康研究院;組織單位:天津市科學技術局;獎項:天津市科學技術進步一等獎類別:抗擊新冠肺炎疫情特別獎。

在新冠肺炎疫情期間,血必淨注射液被中醫和西醫專家聯合推薦納入國家衞生健康委員會和國家中醫藥管理局發佈的《新型冠狀病毒肺炎診療方案(試行第四、五、六、七版)》中,推薦血必淨注射液用於治療重型及危重型病例。為觀察血必淨注射液對重症新冠肺炎的臨牀療效和作用機制,進而開展了“血必淨注射液治療新型冠狀病毒感染的肺炎療效的臨牀和機制研究”項目。

該項目共15個省市的28家分中心參與研究,累計收集276例新冠肺炎病例數據。結果顯示,血必淨注射液能夠明顯改善新冠肺炎患者肺部感染風險等級和病情嚴重程度,提高核酸轉陰率、28天出院率和生存率,且未增加患者的用藥風險。體外抗病毒研究表明,血必淨注射液具有體外抗新冠病毒作用,並且顯著抑制新冠病毒誘導的炎症因子過度釋放。研究結果證明,血必淨注射液對於新冠肺炎導致的全身炎症反應綜合徵、膿毒症和多器官功能障礙具有明確的治療作用。也再次證實血必淨注射液具有治療重症疾病的確切臨牀價值。

公司預計此次獲得的“天津科學技術進步一等獎”將對該產品的市場推廣和銷售產生積極影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account